#None #Amgen #Cardiovascular #Repatha

Amgen's Breakthrough in Cardiovascular Risk Management

Amgen, a leader in biotechnology, has announced a significant milestone for its drug Repatha (evolocumab). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the use of Repatha in adults diagnosed with atherosclerotic cardiovascular disease or those at high risk of its occurrence. This recommendation is expected to pave the way for broader access to this groundbreaking treatment, which focuses on preventing the first occurrences of heart attacks and strokes by significantly lowering LDL cholesterol levels.

Significance of the CHMP Recommendation

The positive opinion from CHMP is built upon a pivotal Phase III clinical trial known as VESALIUS-CV, which included over 12,000 patients and demonstrated that Repatha, when utilized alongside statins and other lipid-lowering therapies, markedly reduced the risk of major adverse cardiovascular events (MACE) for individuals who had not yet suffered a heart attack or stroke. Dr. Paul Burton, Chief Medical Officer at Amgen, emphasized the medical need that still exists in Europe, stating that many patients with high cardiovascular risk are unable to achieve recommended LDL cholesterol levels despite existing therapies.

Unmet Medical Needs

Globally, cardiovascular diseases remain the leading cause of death, with a staggering 99% of individuals experiencing their first cardiovascular event presenting at least one traditional risk factor, such as elevated LDL cholesterol. Despite the European Society of Cardiology's guidelines advocating aggressive LDL-lowering strategies, numerous high-risk patients still do not meet their target cholesterol levels. The CHMP’s endorsement highlights Repatha as a unique solution, given that it is the only PCSK9 inhibitor proven to decrease the risk of the first major cardiovascular incident in clinical trials.

Details of the VESALIUS-CV Trial

The VESALIUS-CV trial was a global, randomized, double-blind, placebo-controlled study that meticulously evaluated the effects of LDL cholesterol reduction through evolocumab on the occurrence of MACE in patients at high risk of cardiovascular events. The trial findings revealed a relative risk reduction of 25% in coronary death, heart attack, and ischemic stroke events (the three-component MACE), while a broader composite endpoint saw a 19% reduction including all arterial revascularization procedures due to ischemia.

Moreover, evolocumab was shown to decrease heart attack risk by 36%. Participants receiving the maximum tolerated dose of statin or ezetimibe indicated significantly lower LDL cholesterol levels, showcasing Repatha's efficacy in augmenting existing cholesterol-lowering treatments.

Future Outlook for Repatha

Originally approved in the European Union back in 2015 for patients with primary hypercholesterolemia and mixed dyslipidemia, Repatha is now poised to redefine cardiovascular care in Europe as the European Commission prepares to make a final decision regarding the new usage indication for the drug. The anticipation surrounding this review underscores the commitment of Amgen in innovating cardiometabolic disease management efforts, aiming to significantly reduce heart disease's burden.

Amgen's Role in Cardiovascular Innovation

Amgen has established itself as a trailblazer in cardiovascular and metabolic disease treatment pathways. With over 40 years of research experience and a focus on human genetics, the company continues to innovate therapies that combat underlying mechanisms contributing to cardiovascular risks. The development of Repatha has paved the way for additional investigational products such as MariTide and olpasiran, designed to address further unmet medical necessities.

As the healthcare community awaits the final verdict from the European Commission, Repatha stands to enhance the standard of care for eligible patients across Europe, potentially transforming the management of cardiovascular disease in populations at risk.